RE:RE:ESMO 2022 - Merck's Keytruda fails in H&N cancer as monotherMarch 21, 2024 - Clinical oncologists are encouraged over the narrow interim OS clinical trial benefit of the combination of pembrolizumab (keytruda) + chemotherapy versus chemotherapy monotherapy in the treatrment of endometrial cancer. where the data showed a median OS of 27.96 months with pembrolizumab (keytruda) + chemotherapy versus 27.37 months with chemotherapy monotherapy, calling this difference as establishing a "new standard of care" for this population of cancer patients.
According to data presented at the meeting, the median OS among patients in the pMMR population was 27.96 months (95% CI, 21.42-not reached [NR]) with pembrolizumab plus chemotherapy vs 27.37 months (95% CI, 19.52-NR) with placebo plus chemotherapy (HR, 0.79; 95% CI, 0.53-1.17; P = .1157). Additionally, the median OS was not reached in either arm among those with dMMR disease (HR, 0.55; 95% CI, 0.25-1.19; P = .0617).
These results further support the addition of ONCY's pelareorep to an immune checkpoint inhibitor + chemotherapy combination to further facilitate the effectiveness of an immune checkpoint inhibitor in the treatment of multiple cancers, through pelareorep's ability to "prime" the innate and adaptive immune system and pelareorep's ability to remodel the tumor microenvironment (TME) in advance of the administration of an immune checkpoint inhibitor.
" Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer."
Findings may help usher in pembrolizumab (Keytruda) plus chemotherapy as a treatment option for patients with endometrial cancer and establish a “new standard” for this population, said Ramez N. Eskander, MD.
Although overall survival (OS) data were immature at the time of the analysis, Eskander highlighted a benefit associated with the pembrolizumab combination in the trial. He stated that he was optimistic these OS data combined with prior progression-free survival (PFS) findings would support pembrolizumab plus chemotherapy as a treatment for those with mismatch repair deficient (dMMR) or mismatch repair proficient (pMMR) disease.
https://www.cancernetwork.com/view/data-may-support-pembrolizumab-chemo-as-new-soc-in-endometrial-cancer